Incyte Reports 2024 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Wall St rises as oil slide offers respite after Fed rate hike
- Oil falls 2% to one-week low as Middle East supply disruption fears ease
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- RBC bullish on Kraft Heinz, sees return to growth in 2027
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Turkish Stocks Fall 6%, Triggering Market-wide Circuit Breaker - Bloomberg
Incyte (INCY) PT Raised to $87 at Leerink Partners
October 30, 2024 6:26 AM EDTLeerink Partners analyst Andrew S. Berens raised the price target on Incyte (NASDAQ: INCY) to $87.00 (from $85.00) while maintaining a Outperform rating.
The analyst comments "Bottom Line: This morning, Incyte reported 3Q24 financial results and provided updates on the pipeline. INCY beat consensus on key product revenues, with... More
Incyte (INCY) PT Raised to $97 at Citi
October 30, 2024 5:47 AM EDTCiti analyst David Lebowitz raised the price target on Incyte (NASDAQ: INCY) to $97.00 (from $92.00) while maintaining a Buy rating.
The analyst comments "Incyte reported 3Q24 results, delivering topline revenue beats due to sustained growth for key franchise drivers in Jakafi and... More
Incyte (INCY) PT Raised to $84 at Jefferies
October 29, 2024 2:41 PM EDTJefferies analyst Kelly Shi raised the price target on Incyte (NASDAQ: INCY) to $84.00 (from $81.00) while maintaining a Buy rating.
The analyst comments "INCY delivered great Q with rev beat ($1.14B vs $1.08B cons) all around - Jakafi $741M (+5% QoQ vs $718M cons) and... More
